AbbVieABBV
Market Cap: $342B
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more call options, than puts
Call options by funds: $2.76B | Put options by funds: $2.08B
10% more repeat investments, than reductions
Existing positions increased: 1,419 | Existing positions reduced: 1,286
0.17% less ownership
Funds ownership: 71.69% [Q1] → 71.52% (-0.17%) [Q2]
1% less funds holding
Funds holding: 3,287 [Q1] → 3,251 (-36) [Q2]
5% less capital invested
Capital invested by funds: $230B [Q1] → $218B (-$12.3B) [Q2]
20% less first-time investments, than exits
New positions opened: 147 | Existing positions closed: 183
22% less funds holding in top 10
Funds holding in top 10: 220 [Q1] → 172 (-48) [Q2]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
13 analyst ratings
Piper Sandler Christopher Raymond 43% 1-year accuracy 12 / 28 met price target | 8%upside $209 | Overweight Maintained | 23 Aug 2024 |
Morgan Stanley Terence Flynn 75% 1-year accuracy 15 / 20 met price target | 13%upside $218 | Overweight Maintained | 12 Aug 2024 |
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 3%upside $200 | Overweight Reiterated | 5 Aug 2024 |
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 3%upside $200 | Overweight Reiterated | 26 Jul 2024 |
Truist Securities Robyn Karnauskas 43% 1-year accuracy 20 / 47 met price target | 9%upside $210 | Buy Reiterated | 26 Jul 2024 |
Financial journalist opinion
Based on 45 articles about ABBV published over the past 30 days